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Abstract 
Background: DNA methylation is an epigenetic modification that has the ability to alter gene expression and 
function. These epigenetic changes have been associated with the development of cancer. Previous research has 
found that DNA methylation patterns can predict disease prognosis for patients with Acute Promyelocytic 
Leukemia (APL). The role of DNMT1 and CDH1 in regulating the extension of cells are studied in this study. 
Methods: DNA was extracted from peripheral blood samples of APL patients and treated with bisulfite. 
DNMT1 and CDH1 gene promoter methylation was subsequently analyzed using methylation-specific PCR 
(MSP). Real-time PCR was used to measure the expression level of DNMT1 and CDH1 genes. 
Results: Partial methylation of the CDH1 gene promoter was detected in 20% of APL patients and an 
unmethylated status was detected in 80% of patient samples. Additionally, an unmethylated status in the DNMT1 
gene promoter was detected in 100% of APL patient samples.  
Conclusions: Our study found the CDH1 gene promoter to be unmethylated in almost all APL patients, while 
the DNMT1 promoter was unmethylated in all APL patients. Furthermore, we observed an increase in both 
CDH1 and DNMT1 gene expression in APL patients compared to healthy controls. These findings suggest that 
DNMT1 may not have a specific role in inhibiting CDH1 gene expression in APL. Applying higher resolution 
techniques would help to better uncover the DNA methylation patterns in patients with APL. Further research 
is required to determine the role of DNA methylation and CDH1 and DNMT1 gene expression in APL. 
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Introduction 
Acute myeloid leukemia (AML) is a 
hematopoietic malignancy in which incompletely 
differentiated hematopoietic progenitor cells 
accumulate in the bone marrow and blood, 
interfering with normal hematopoiesis. Research 
has shown that the accumulation of mutations and 
epigenetic modifications are key features in the 
AML genome. Both of these alterations often occur 
prior to the development of leukemia and persist in 
residual disease following therapeutic intervention. 
 
 
Thus, targeting the AML epigenome may help cure 
the residual disease and prevent cancer recurrence 
(1). The treatment interventions for AML have 
remained relatively unchanged over the past few 
decades, however there have been some 
improvements in the survival outcomes for younger 
patients (2). In spite of these improvements, AML 
treatment interventions are unsuccessful for about 
60% of young patients (3). In patients over the age 
of 60, in which there is an increased frequency of 
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